Weighing a mortality imbalance in one clinical trial with the need for new antibacterials amid growing drug resistance, the FDA's Antimicrobial Drugs Advisory Committee gave its support Wednesday for the approval of Paratek Pharmaceuticals Inc.'s omadacycline, the first of a new generation of tetracycline drugs known as aminomethylcyclines.